Sangamo Therapeutics (SGMO) Leases (2019 - 2025)
Sangamo Therapeutics (SGMO) has 7 years of Leases data on record, last reported at $14.4 million in Q3 2025.
- For Q3 2025, Leases fell 18.79% year-over-year to $14.4 million; the TTM value through Sep 2025 reached $14.4 million, down 18.79%, while the annual FY2024 figure was $16.9 million, 35.1% down from the prior year.
- Leases reached $14.4 million in Q3 2025 per SGMO's latest filing, down from $15.1 million in the prior quarter.
- Across five years, Leases topped out at $73.2 million in Q4 2021 and bottomed at $14.4 million in Q3 2025.
- Average Leases over 5 years is $42.8 million, with a median of $46.8 million recorded in 2023.
- Peak YoY movement for Leases: grew 3.01% in 2021, then plummeted 60.08% in 2024.
- A 5-year view of Leases shows it stood at $73.2 million in 2021, then dropped by 15.28% to $62.0 million in 2022, then tumbled by 58.08% to $26.0 million in 2023, then crashed by 35.1% to $16.9 million in 2024, then fell by 14.47% to $14.4 million in 2025.
- Per Business Quant database, its latest 3 readings for Leases were $14.4 million in Q3 2025, $15.1 million in Q2 2025, and $16.0 million in Q1 2025.